Naphtho[1,2-d]isothiazole acetic acid derivatives as a novel class of selective aldose reductase inhibitors

Journal of Medicinal Chemistry

Volumn 48, Issue 22, 2005, Pages 6897-6907

  Da Settimo, Federico ^a   Primofiore, Giampaolo ^a   La Motta, Concettina ^a   Sartini, Stefania ^a   Taliani, Sabrina ^a   Simorini, Francesca ^a   Marini, Anna Maria ^a   Lavecchia, Antonio ^b   Novellino, Ettore ^b   Boldrini, Enrico ^c  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Opocrin SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(1,3,3 TRIOXO 1,2 DIHYDRONAPHTHO[1,2 D]ISOTHIAZOL 2 YL)ACETIC ACID; 2 BENZYL 1,3,3 TRIOXO 1,2 DIHYDRONAPHTHO[1,2 D]ISOTHIAZOLE 4 CARBOXYLIC ACID; 2 CARBOXYMETHYL 1,3,3 TRIOXO 1,2 DIHYDRONAPHTHO[1,2 D]ISOTHIAZOLE 4 CARBOXYLIC ACID; 2 CARBOXYMETHYL 1,3,3 TRIOXO 1,2 DIHYDRONAPHTHO[1,2 D]ISOTHIAZOLE 4 CARBOXYLIC ACID CARBOXYMETHYL ESTER; 2 ISOPROPOXYCARBONYLMETHYL 1,3,3 TRIOXO 1,2 DIHYDRONAPHTHO[1,2 D]ISOTHIAZOLE 4 CARBOXYLIC ACID ISOPROPYL ESTER; 2 METHYL 1,3,3 TRIOXO 1,2 DIHYDRONAPHTHO[1,2 D]ISOTHIAZOLE 4 CARBOXYLIC ACID; ACETIC ACID DERIVATIVE; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; EPALRESTAT; GLUTATHIONE REDUCTASE; IDITOL DEHYDROGENASE; NAPHTHO[1,2 D]ISOTHIAZOLE ACETIC ACID DERIVATIVE; PRODRUG; QUERCETIN; SORBINIL; TOLRESTAT; UNCLASSIFIED DRUG; ZOPOLRESTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATARACT; CATARACTOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; NONHUMAN; RAT; SIMULATION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THEORY;

ACETIC ACIDS; ALDEHYDE REDUCTASE; ANIMALS; BINDING SITES; CATARACT; CRYSTALLOGRAPHY, X-RAY; GALACTOSEMIAS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NAPHTHALENES; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 27444440949     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050382p     Document Type: Article

References (56)

1. King, H.; Aubert, R. E.; Herman, W. H. Global Burden of Diabetes, 1995-2025. Prevalence, Numeric Estimates, and Projections. Diabetes Care 1998, 21, 1414-1431.
2. Bressler, R.; Johnson, D. New Pharmacological Approaches to Therapy of NIDDM. Diabetes Care 1992, 15, 792-805.
3. Mahon, J. L.; Dupre, J.; Stiller, C. R. Lessons Learned from Use of Cyclosporine for Insulin-Dependent Diabetes Mellitus. The Case of Immunotherapy for Insulin-Dependent Diabetics Having Residual Insulin Secretion. Ann. N.Y. Acad. Sci. 1993, 696, 3651-3663.
4. Brownlee, M. Biochemistry and Molecular Cell Biology of Diabetic Complications. Nature 2001, 414, 813-820.
5. Scott, J. A.; King, G. L. Oxidative Stress and Antioxidant Treatment in Diabetes. Ann. N.Y. Acad. Sci. 2004, 1031, 204-213.
6. Whiteside, C. I. Cellular Mechanisms and Treatment of Diabetes Vascular Complications Converge on Reactive Oxygen Species. Curr. Hypertens. Rep. 2005, 7, 148-154.
7. Brownlee, M. The Pathological Implications of Protein Glycation. Clin. Invest. Med. 1995, 18, 275-281.
8. Tomlinson, D. R.; Stevens, E. J.; Diemel, L. T. Aldose Reductase Inhibitors and Their Potential for the Treatment of Diabetic Complications. Trends Pharmacol. Sci. 1994, 15, 293-297.
9. Kador, P. F. The Role of Aldose Reductase in the Development of Diabetic Complications. Med. Res. Rev. 1988, 8, 325-352.
10. Bravi, M. C.; Pietrangeli, P.; Laurenti, O.; Basili, S.; Cassone-Faldetta, M.; Ferri, C.; De Mattia, C. Polyol Pathway Activation and Glutathione Redox Status in Non-Insulin-Dependent Diabetic Patients. Metabolism 1997, 46, 1194-1198.
11. Cheng, H. M.; Gonzales, R. G. The Effect of High Glucose and Oxidative Stress on Lens Metabolism, Aldose Reductase, and Senile Cataractogenesis. Metabolism 1986, 35, 10-14.
12. Chung, S. S. M.; Ho, E. C. M.; Lam, K. S. L.; Chung, S. K. Contribution of Polyol Pathway to Diabetes-Induced Oxidative Stress. J. Am. Soc. Nephrol. 2003, 14, S234-S236.
13. Morre, D. M.; Lenaz, G.; Morre, D. J. Surface Oxidase and Oxidative Stress Propagation in Aging. J. Exp. Biol. 2000, 203, 1513-1521.
14. Sarges, R.; Oates, P. J. Aldose Reductase Inhibitors: Recent Developments. Prog. Drug Res. 1993, 40, 99-161.
15. Wilson, D. K.; Tarle, I.; Petrash, J. M.; Quiocho, F. A. Refined 1.8 Å Structure of Human Aldose Reductase Complexed with the Potent Inhibitor Zopolrestat. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 9847-9851.
16. Urzhumtsev, A.; Tête-Favier, F.; Mitschler, A.; Barbanton, J.; Barth, P.; Urzhumtseva, L.; Biellmann, J.-F.; Podjarny, A. D.; Moras, D. A "Specificity" Pocket Inferred from the Crystal Structures of the Complexes of Aldose Reductase with the Pharmaceutically Important Inhibitors Tolrestat and Sorbinil. Structure 1997, 5, 601-612.
17. Harrison, D. H. T.; Bohren, K. M.; Petsko, G. A.; Ringe, D.; Gabbay, K. H. The Alrestatin Double-Decker: Binding of Two Inhibitor Molecules to Human Aldose Reductase Reveals a New Specificity Determinant. Biochemistry 1997, 36, 16134-16140.
18. Harrison, D. H.; Bohren, K. M.; Ringe, D.; Petsko, G. A.; Gabbay, K. H. An Anionic Binding Site in Human Aldose Reductase: Mechanistic Implications for the Binding of Citrate, Cacodylate, and Glucose-6-phosphate. Biochemistry 1994, 33, 2011-2020.
19. Carper, D.; Wistow, G.; Nishimura, C.; Graham, C.; Watanabe, K.; Fuji, Y.; Hayaishi, H.; Hayaishi, O. A Superfamily of NADPH-Dependent Reductases in Eukaryotes and Prokaryotes. Exp. Eye Res. 1988, 49, 377-388.
20. Costantino, L.; Rastelli, G.; Vescovini, K.; Cignarella, G.; Vianello, P.; Del Corso, A.; Cappiello, M.; Mura, U.; Barlocco, D. Synthesis, Activity, and Molecular Modeling of a New Series of Tricyclic Pyridazinones as Selective Aldose Reductase Inhibitors. J. Med. Chem. 1996, 39, 4396-4405.
21. Kador, P. F.; Inoue, J.; Secchi, E. F.; Lizak, M. J.; Rodriguez, L.; Mori, K.; Greentree, W.; Blessing, K.; Lackner, P. A.; Sato, S. Effect of Sorbitol Dehydrogenase Inhibition on Sugar Cataract Formation in Galactose-Fed and Diabetic Rats. Exp. Eye Res. 1998, 67, 203-208.
22. Giblin, F. J.; McCready, J. P.; Schrimscher, L.; Reddy, V. N. Peroxide-Induced Effects on Lens Cation Transport Following Inhibition of Glutathione Reductase Activity in Vitro. Exp. Eye Res. 1987, 45, 77-91.
23. Reddan, J. R.; Giblin, F. J.; Dziedzic, D. C.; McCready, J. P.; Schrimscher, L.; Reddy, V. N. Influence of the Activity of Glutathione Reductase on the Response of Cultured Lens Epithelial Cells from Young and Old Rabbits to Hydrogen Peroxide. Exp. Eye Res. 1998, 46, 209-221.
24. Da Settimo, F.; Primofiore, G.; Da Settimo, A.; La Motta, C.; Taliani, S.; Simorini, F.; Novellino, E.; Greco, G.; Lavecchia, A.; Boldrini, E. [1,2,4]Triazino[4,3-a]benzimidazole Acetic Acid Derivatives: A New Class of Selective Aldose Reductase Inhibitors. J. Med. Chem. 2001, 44, 4359-4369.
25. Da Settimo, F.; Primofiore, G.; Da Settimo, A.; La Motta, C.; Simorini, F.; Novellino, E.; Greco, G.; Lavecchia, A.; Boldrini, E. Novel, Highly Potent Aldose Reductase Inhibitors: Cyano-(2-oxo-2,3-dihydroindol-3-yl)acetic Acid Derivatives. J. Med. Chem. 2003, 46, 1419-1428.
26. Da Settimo, A.; Primofiore, G.; La Motta, C.; Da Settimo, F.; Simorini, F.; Boldrini, E.; Bianchini, P. Acid Derivatives of Benzisothiazole-1,1-dioxide as Inhibitors of Rat Lens Aldose Reductase. Farmaco 1996, 51, 261-267.
27. Primofiore, G.; Da Settimo, F.; La Motta, C.; Simorini, F.; Minutolo, A.; Boldrini, E. Benzisothiazole-1,1-dioxide Alkanoic Acid Derivatives as Inhibitors of Rat Lens Aldose Reductase. Farmaco 1997, 52, 583-588.
28. Wrobel, J.; Dietrich, A.; Gorham, B. J.; Sestanj, K. Conformationally Rigid Analogues of Aldose Reductase Inhibitors, Tolrestat. Novel Syntheses of Naphthalene-Fused γ-, δ-, and ε-Lactams. J. Org. Chem. 1990, 55, 2694-2702.
29. El-Kabbani, O.; Wilson, D. K.; Petrash, J. M.; Quiocho, F. A. Structural Features of the Aldose Reductase and Aldehyde Reductase Inhibitor-Binding Sites. Mol. Vision 1998, 4, 19-25.
30. Lombardino, J. G. Preparation of Substituted 1,2-Benzoisothiazolin-3-one- 1,1-dioxides (o-Benzoic Sulfimides). J. Org. Chem. 1971, 36, 1843-1845.
31. Nicolaou, I.; Demopoulos, V. J. Substituted Pyrrol-1-ylacetic Acids That Combine Aldose Reductase Enzyme Inhibitory Activity and Ability To Prevent the Nonenzymatic Irreversible Modification of Proteins from Monosaccharides. J. Med. Chem. 2003, 46, 417-426.
32. Boissonnas, R. A.; Guttmann, St.; Jaquenoud, P.-A.; Waller, J.-P. Synthèse d'Analogues Structuraux de L'oxytocine (Synthesis of Structural Analogues of Oxytocin). Helv. Chim. Acta 1956, 39, 1421-1427.
33. Coudert, P.; Albuisson, E.; Boire, J. Y.; Durox, E.; Bastide, P.; Couquelet, J. Synthesis of Pyridazine Acetic Acid Derivatives Possessing Aldose Reductase Inhibitory Activity and Antioxidant Properties. Eur. J. Med. Chem. 1994, 29, 471-477.
34. Banditelli, S.; Boldrini, E.; Vilardo, G. P.; Cecconi, I.; Cappiello, M.; Dal Monte, M.; Marini, I.; Del Corso, A.; Mura, U. A New Approach against Sugar Cataract through Aldose Reductase Inhibitors. Exp. Eye Res. 1999, 69, 533-538.
35. 2α and Its Isopropyl Ester in Vitro. Int. J. Pharm. 1987, 37, 27-32.
36. Suhonen, P.; Järvinen, T.; Peura, P.; Urtti, A. Permeability of Pilocarpic Acid Diesters across Albino Rabbit Cornea in Vitro. Int. J. Pharm. 1991, 74, 221-228.
37. 2α Prodrugs in Rabbit Cornea and Conjunctiva. J. Pharm. Sci. 1997, 86, 1180-1186.
38. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function. J. Comput. Chem. 1998, 19, 1639-1662.
39. Database searching (SWISS-PROT), sequence alignment, and analysis of rat and pig ALR2 sequences were carried out using FASTA (Pearson, W. R. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 2444-2448)
40. and BLAST programs (Wang, S.; Pak, Y. J. Phys. Chem. B 2000, 104, 354-359). The SWISS-PROT accession numbers for rat and pig ALR2 types are P07943 and P80276, respectively.
41. Harrison, D. H. T.; Bohren, K. M.; Petsko, G. A.; Ringe, D.; Gabbay, K. H. The Alrestatin Double-Decker: Binding of Two Inhibitor Molecules to Human Aldose Reductase Reveals a New Specificity Determinant. Biochemistry 1997, 36, 16134-16140.
42. Rogniaux, H.; Van Dorsselaer, A.; Barth, P.; Biellmann, J.-F.; Barbanton, J.; Van Zandt, M.; Chevrier, B.; Howard, E.; Mitschler, A.; Potier, N.; Urzhumtseva, L.; Moras, D.; Podjarny, A. Binding of Aldose Reductase Inhibitors: Correlation of Crystallographic and Mass Spectrometric Studies. J. Am. Soc. Mass Spectrom. 1999, 10, 635-647.
43. Bohren, K. M.; Grimshaw, C. E.; Lai, C. J.; Harrison, D. H.; Ringe, D.; Petsko, G. A.; Gabbay, K. H. Tyrosine-48 Is the Proton Donor and Histidine-110 Directs Substrate Stereochemical Selectivity in the Reduction Reaction of Human Aldose Reductase: Enzyme Kinetics and Crystal Structure of the Y48H Mutant Enzyme. Biochemistry 1994, 33, 2021-2032.
44. Grimshaw, C. E.; Bohren, K. M.; Lai, C. J.; Gabbay, K. H. Human Aldose Reductase: pK of Tyrosine 48 Reveals the Preferred Ionization State for Catalysis and Inhibition. Biochemistry 1995, 34, 14374-14384
45. El-Kabbani, O.; Carper, D. A.; McGowan, M. H.; Devedjiev, Y.; Milton, K. J.; Flynn, T. G. Studies on the Inhibitor-Binding Site of Porcine Aldehyde Reductase: Crystal Structure of the Holoenzyme-Inhibitor Ternary Complex. Proteins 1997, 28, 186-192.
46. Hayman, S.; Kinoshita, J. H. Isolation and Properties of Lens Aldose Reductase. J. Biol. Chem. 1965, 240, 877-882.
47. Ward, W. H. J.; Sennitt, C. M.; Ross, H.; Dingle, A.; Timmus, D.; Mirrless, D. J.; Tuffin, D. P. Ponalrestat, a Potent and Specific Inhibitor of Aldose Reductase. Biochem. Pharmacol. 1990, 39, 337-346.
48. Lindstad, R. I.; Hermansen, L. F.; McKinley-McKee, J. S. Inhibition and activation studies on sheep liver sorbitol dehydrogenase. Eur. J. Biochem. 1994, 221, 847-854.
49. Fitzgerald, G. B.; Bauman, C.; Sajjat Hussoin, Md.; Wick, M. M. 2,4-Dihydroxy benzylamine: a specific inhibitor of glutathione reductase. Biochem. Pharmacol. 1991, 41, 185-190.
50. SYBYL Molecular Modelling System, version 6.9.1; Tripos Inc.: St. Louis, MO, 2003.
51. Vinter, J. G.; Davis, A.; Saunders, M. R. Strategic Approaches to Drug Design. 1. An Integrated Software Framework for Molecular Modelling. J. Comput.-Aided Mol. Des. 1987, 1, 31-55.
52. Insight II Molecular Modelling Package and Discover 2. 2000 Simulation Package; MSI Inc.: San Diego, CA, 2000.
53. Hagler, A. F.; Lifson, S.; Dauber, P. Consistent Force Field Studies of Intermolecular Forces in Hydrogen-Bonded Crystals. J. Am. Chem. Soc. 1979, 101, 5122-5130.
54. Head, J.; Zerner, M. C. A Broyden-Fletcher-Goldfarb-Shannon Optimization Procedure for Molecular Geometries. Chem. Phys. Lett. 1985, 122, 264-274.
55. Gasteiger, J.; Marsili, M. Iterative Partial Equalization of Orbital Electronegativity. A Rapid Access to Atomic Charges. Tetrahedron 1980, 36, 3219-3228.
56. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F., Jr.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, T. The Protein Data Bank: A Computer Based Archival File for Macromolecular Structures. J. Mol. Biol. 1977, 112, 535-542.